The surveillance regarding the ultra-rapid insulin glulisine (Apidra)

The surveillance regarding the ultra-rapid insulin glulisine (Apidra) - The surveillance regarding the ultra-rapid insulin glulisine (Apidra)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006908

Enrollment

Registered

2012-03-01

Start date

2015-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type1 Diabetes

Interventions

Randomized cross-over trial divided with the usual insulin group (Group1) and the Apidra group (Group2) for totally six months. After using three months, the usual insulin in (Group1) is changed into

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The current CSII patients who can agree to the examination, selected by the doctor properly.

Exclusion criteria

Exclusion criteria: 1) Pregnant 2) Patient that doctor cannot screen properly because of any reason.

Design outcomes

Primary

Measure	Time frame
FPG/PPG, Hba1c, 1.5AG, the amount of Insulin, Hypoglycemia, Quality of Life(QOL)	—

Countries

Japan

Contacts

Public ContactYoichi Imamura

aozora clinic Internal medicine

aozoraclimamura@forest.on.ne.jp0942-94-9811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026